top of page

Researchers develop ultra-high-performance method to analyze oxylipins

NDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, scientists from RIDC Redoxoma led by researcher Dr. Sayuri Miyamoto from the Institutode Química at Universidade de São Paulo (USP), established and validated an ultra-high performance liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS) method for simultaneous analysis of 126 oxylipins in plasma. With this tool, they analyzed the plasma of an animal model of ALS and found altered oxylipins in symptomatic animals that reflect oxidative stress, inflammation, and lipid hypermetabolism. According to the researchers,oxylipins can become biomarkers for monitoring disease progression. The article Plasma oxylipin profiling by high resolution mass spectrometry reveal signatures of inflammation and hypermetabolism in amyotrophic lateral sclerosis, by Adriano B. Chaves-Filho, Larissa S. Diniz, Rosangela S. Santos, Rodrigo S. Lima, Hector Oreliana, IsabellaF.D. Pinto, Lucas S. Dantas, Alex Inague, Rodrigo L. Faria,Marisa H.G. Medeiros, IsaíasGlezer, William T. Festuccia, Marcos Y. Yoshinaga and Sayuri Miyamoto, can be accessed here

14 views0 comments

Recent Posts

See All

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

bottom of page